Skip to main content
SpringerLink
Log in

Therapie der idiopathischen Lungenfibrose

Therapy of idiopathic pulmonary fibrosis

  • Journal Club
  • Published:
Der Pneumologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Richeldi L, Bois RM du, Raghu G et al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370:2071–2082

    Article  PubMed  Google Scholar 

  2. King TE, Bradford WZ, Castro-Bernardini S et al (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370:2083–2092

    Article  PubMed  Google Scholar 

  3. The Idiopathic Pulmonary Fibrosis Network (2014) Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 370:2093–2101

    Article  Google Scholar 

  4. Demedts M, Behr J, Buhl R et al (2005) High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 353:2229–2242

    Article  CAS  PubMed  Google Scholar 

  5. The Idiopathic Pulmonary Fibrosis Clinical Research Network (2012) Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 366:1968–1977

    Article  Google Scholar 

  6. Raghu G, Collard HR, Egan JJ et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824

    Article  PubMed  Google Scholar 

  7. Behr J, Günther A, Ammenwerth W et al (2013) S2K-Leitlinie zur Diagnostik und Therapie der idiopathischen Lungenfibrose. Pneumologie 67:81–111

    Article  CAS  PubMed  Google Scholar 

  8. Noble PW, Albera C, Bradford WZ et al (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials. Lancet 377:1760–1769

    Article  CAS  PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. J. Schreiber hat Vortrags- und Beratertätigkeiten für Intermune und Boehringer übernommen. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Abteilung für Pneumologie, Universitätsklinikum Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Deutschland

    J. Schreiber

Authors
  1. J. Schreiber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Schreiber.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schreiber, J. Therapie der idiopathischen Lungenfibrose. Pneumologe 11, 433–436 (2014). https://doi.org/10.1007/s10405-014-0819-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10405-014-0819-3

Search

Navigation